Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals (...) Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met: 1. Patient has a contraindication to less expensive antipsychotic agents, or 2. Patient has failed a trial of less expensive antipsychotics because of intolerance

2014 Health Technology Assessment (HTA) Database.

162. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion

2014 Health Technology Assessment (HTA) Database.

163. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would

2014 Health Technology Assessment (HTA) Database.

164. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low-potency antipsychotic drugs are often clinically perceived as less efficacious than high-potency compounds, and they also seem to differ in their side-effects.To review the effects in clinical response of haloperidol and low-potency (...) antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (July 2010).We included all randomised trials comparing haloperidol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For dichotomous data, we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we

2014 Cochrane

165. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low-potency antipsychotic drugs are often perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side-effects.To review the effects in response to treatment (...) of trifluoperazine and low-potency antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (November 2010).We included all randomised trials comparing trifluoperazine with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects

Full Text available with Trip Pro

2014 Cochrane

166. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. (PubMed)

Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Long-acting depot injections of drugs such as flupenthixol decanoate are extensively used as a means of long-term maintenance treatment for schizophrenia.To evaluate the effects of flupenthixol decanoate in comparison with placebo, oral antipsychotics and other depot neuroleptic preparations for people with schizophrenia and other severe mental illnesses, in terms of clinical, social and economic outcomes.We (...) identified relevant trials by searching the Cochrane Schizophrenia Group Trials Register in March 2009 and then for this update version, a search was run in April 2013. The register is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. We contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.All randomised controlled trials that focused on people

2014 Cochrane

167. Horticultural therapy for schizophrenia. (PubMed)

Horticultural therapy for schizophrenia. Horticultural therapy is defined as the process of utilising fruits, vegetables, flowers and plants facilitated by a trained therapist or healthcare provider, to achieve specific treatment goals or to simply improve a person's well-being. It can be used for therapy or rehabilitation programs for cognitive, physical, social, emotional, and recreational benefits, thus improving the person's body, mind and spirit. Between 5% to 15% of people (...) with schizophrenia continue to experience symptoms in spite of medication, and may also develop undesirable adverse effects, horticultural therapy may be of value for these people.To evaluate the effects of horticultural therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care or other additional psychosocial interventions.We searched the Cochrane Schizophrenia Group Trials Register (Janurary 2013) and supplemented this by contacting relevant study authors, and manually

Full Text available with Trip Pro

2014 Cochrane

168. Pericyazine for schizophrenia. (PubMed)

Pericyazine for schizophrenia. Pericyazine is a 3-cyano-10 (3-4'-hydroxypiperidinopropyl) phenothiazine. It is overall pharmacologically similar with chlorpromazine, though particularly sedating. Dopamine receptor subtype analysis has not been performed for pericyazine, but the drug appears to induce greater noradrenergic than dopaminergic blockade. Compared to chlorpromazine, pericyazine reportedly has more potent antiemetic, antiserotonin, and anticholinergic activity.To evaluate the clinical (...) effects and safety of pericyazine in comparison with placebo, typical and atypical antipsychotic agents and standard care for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (February 2013) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials.All relevant randomised controlled trials focusing on pericyazine for schizophrenia and other types of schizophrenia-like psychoses

Full Text available with Trip Pro

2014 Cochrane

169. Carbamazepine for schizophrenia. (PubMed)

Carbamazepine for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication (...) is an effective treatment for the same illnesses.For the original version we searched The Cochrane Schizophrenia Group's Register of Trials (December 2001), The Cochrane Library (Issue 3, 2001), MEDLINE (1966-2001), EMBASE (1980-2001), Biological Abstracts (1980-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). For the most recent update we searched the Cochrane Schizophrenia Group's Register of Trials in July 2012. We also inspected references of all identified studies for further trials and contacted

2014 Cochrane

170. Smoking cessation in patients with schizophrenia

Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smoking cessation in patients with schizophrenia. Lansdale: HAYES, Inc.. Directory Publication. 2014 Authors' conclusions The purpose of smoking cessation therapies (...) is to decrease smoking and smoking-related morbidity and mortality in patients. Interventions for smoking cessation may be pharmacologic and/or psychosocial. This report focuses on smoking cessation therapies in patients with schizophrenia. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Schizophrenia; Smoking Cessation Language Published English Country of organisation United States English summary An English language summary is available

2014 Health Technology Assessment (HTA) Database.

171. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. (PubMed)

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs.We did (...) a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation

Full Text available with Trip Pro

2014 Lancet

172. Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. (PubMed)

Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. Observational evidence suggests that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middle-income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the effectiveness of a collaborative (...) community-based care intervention with standard facility-based care.We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 and Dec 31, 2010. Patients aged 16-60 years with a primary diagnosis of schizophrenia according to the tenth edition of the International Classification of Diseases, Diagnostic Criteria for Research (ICD-10-DCR) were randomly assigned (2:1), via a computer-generated randomisation list with block sizes of three, six, or nine

Full Text available with Trip Pro

2014 Lancet

173. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. (PubMed)

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed

2014 Cochrane

174. Family intervention (brief) for schizophrenia. (PubMed)

Family intervention (brief) for schizophrenia. Supportive, positive family environments have been shown to improve outcomes for patients with schizophrenia in contrast with family environments that express high levels of criticism, hostility, or over-involvement, which have poorer outcomes and have more frequent relapses. Forms of psychosocial intervention, designed to promote positive environments and reduce these levels of expressed emotions within families, are now widely used.To assess (...) the effects of brief family interventions for people with schizophrenia or schizophrenia-like conditions.We searched the Cochrane Schizophrenia Group Trials Register (July 2012), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted authors of trials for additional information.All relevant randomised studies that compared brief family-oriented psychosocial interventions with standard care, focusing

Full Text available with Trip Pro

2014 Cochrane

175. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have (...) -effectiveness of lurasidone, compared with aripiprazole, for treating adult patients with schizophrenia, who had failed to respond to generic atypical antipsychotics. The authors concluded that lurasidone was less costly and more effective than aripiprazole. The results and modelling were well reported, but given the uncertainty around the use of all the best evidence available, the authors' conclusions may need to be interpreted with caution. Type of economic evaluation Cost-effectiveness analysis Study

2014 NHS Economic Evaluation Database.

176. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia

Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, Zilbershtein R, Jensen RC, Hemels ME, Einarson TR Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of long-acting injectable paliperidone palmitate for people with stable chronic schizophrenia and a history of relapse and hospitalisation. The authors concluded that paliperidone was the most cost-effective long-acting injectable atypical

Full Text available with Trip Pro

2014 NHS Economic Evaluation Database.

177. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. (PubMed)

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs.We did (...) a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation

Full Text available with Trip Pro

2014 Lancet

178. Perazine for schizophrenia. (PubMed)

Perazine for schizophrenia. Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia and is reputed to have a low level of extrapyramidal adverse effects. As far as we are aware, its use is limited to Germany, Poland, the former Yugoslavia and the Netherlands.To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications.We searched the Cochrane Schizophrenia (...) for people with schizophrenia or schizophrenia-like psychoses, or both.The review authors (SL, BH, BHe) independently inspected the citations and where possible abstracts and ordered papers for re-inspection and quality assessment. We independently extracted data. We calculated the risk ratio (RR) and 95% confidence interval (CI) using a random-effects model. For continuous data, we calculated mean differences (MD). We inspected all data for heterogeneity, assessed trials for risk of bias and created

Full Text available with Trip Pro

2014 Cochrane

179. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. (PubMed)

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. It is estimated that more than half of those with serious mental illness smoke tobacco regularly. Standard courses of pharmacotherapeutic cessation aids improve short-term abstinence, but most who attain abstinence relapse rapidly after discontinuation of pharmacotherapy.To determine whether smokers diagnosed with schizophrenia and bipolar disease have (...) higher rates of prolonged tobacco abstinence with maintenance pharmacotherapy than with standard treatment.Randomized, double-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 community mental-health centers. Of 247 smokers with schizophrenia or bipolar disease recruited from March 2008-April 2012, 203 received 12-weeks' open-label varenicline and cognitive behavioral therapy and 87 met abstinence criteria to enter the relapse prevention

Full Text available with Trip Pro

2014 JAMA

180. Chlorpromazine versus placebo for schizophrenia. (PubMed)

Chlorpromazine versus placebo for schizophrenia. Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia.To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information.We (...) included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non-affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care.We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95

2014 Cochrane